Welcome to our dedicated page for Biophytis SA news (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis SA stock.
Biophytis S.A. reports clinical-stage biotechnology developments centered on treatments for age-related diseases. Recurring updates focus on BIO101 (20-hydroxyecdysone), the company’s lead small-molecule drug candidate, across obesity, sarcopenia, Duchenne muscular dystrophy, and respiratory indications including severe forms of Covid-19.
Company news also covers regulatory submissions and authorizations for clinical studies, presentations of trial results, manufacturing scale-up for GMP-compliant supply, licensing and partnership activity in Latin America and Asia, and periodic financial results. The issuer’s American depositary security reflects parent-company announcements from Biophytis S.A. and its public-company disclosures.
Biophytis SA (NasdaqCM: BPTS) announced its 2020 financial results and key operational updates. Major milestones include the launch of the phase 2-3 COVA trial for Sarconeos (BIO101) to treat COVID-19 related acute respiratory failure, with patient enrollment completed for Part 1. The company's financial position improved, with cash and equivalents rising to €18.8 million. Despite a net loss of €17.1 million, this was an improvement from €17.8 million in 2019. The company successfully raised €23.4 million through private placements, bolstering its operational capacity.
Biophytis announces the commencement of recruitment for Part 2 of its COVA Study in France and Belgium, following regulatory approvals. This follows earlier authorizations in Brazil and the USA. Part 1 has enrolled 50 participants, with an interim analysis expected in Q1 2021 and full results from both parts anticipated in Q2 2021. The study evaluates Sarconeos (BIO101) as a treatment for severe respiratory failure in COVID-19 patients aged 45 and older, building on its proof of concept data from Part 1.
Biophytis announced the closure of its initial public offering, raising approximately $20.1 million in gross proceeds on February 12, 2021. This offering involved the sale of 1,200,000 American Depositary Shares (ADSs) at an offering price of $16.75 per ADS. The net proceeds are estimated to be around $16.35 million after deducting expenses. Biophytis focuses on developing therapeutics for age-related diseases, particularly respiratory failure in COVID-19 patients. The company's ADSs began trading on the Nasdaq under the ticker symbol BPTS on February 10, 2021.
Biophytis announced the resumption of trading for its ordinary shares and share warrants on Euronext Growth, starting February 10, 2021, at 4 p.m. CET. Trading was suspended earlier that day to facilitate a public offering on the Nasdaq Capital Market, ensuring smooth allocation confirmations for investors. The company focuses on developing therapeutics aimed at slowing degenerative processes linked to aging and improving outcomes for patients with age-related diseases, particularly severe respiratory failure in COVID-19 patients.
Biophytis has announced a U.S. initial public offering pricing of 12 million new ordinary shares, represented by 1.2 million American Depositary Shares (ADSs), at $16.75 per ADS, aiming for gross proceeds of $20.1 million. The offering is set to close around February 12, 2021. The proceeds will primarily fund clinical trials for its drug Sarconeos (BIO101) related to COVID-19 and sarcopenia, with additional funds allocated for research and general corporate purposes. The ADSs are expected to begin trading on Nasdaq under the symbol BPTS.
On February 10, 2021, Biophytis announced a temporary halt in trading of its shares on Euronext Growth as it prepares for its initial public offering of American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol BPTS. The halt is in effect from 9 a.m. CET and is expected to last until approximately 4 p.m. CET, when Euronext trading will resume. The IPO aims to gain capital for developing therapeutics focused on age-related diseases, including severe respiratory failure linked to COVID-19.